Figure 3
Kaplan-Meier PFS and OS estimates. Survival analysis included 35 patients with evaluable disease completing at least 2 cycles of lenalidomide. Median PFS was 4 months (95% CI: 2-6) and the median OS was 20 months (95% CI: 15-NE).
Kaplan-Meier PFS and OS estimates. Survival analysis included 35 patients with evaluable disease completing at least 2 cycles of lenalidomide. Median PFS was 4 months (95% CI: 2-6) and the median OS was 20 months (95% CI: 15-NE).
